IQVIA Holdings Inc. (IQV) Return on Assets (ROA): 4.67%
Is IQVIA Holdings Inc.’s return on assets (ROA) high or low?
IQVIA Holdings Inc.'s return on assets (ROA) of 4.67% is 16% above its 5-year average of 4.01%, near the high end of its 5-year range (1.14%–5.10%).
The return on assets (ROA) for IQVIA Holdings Inc. (IQV) is 4.67% as of Wednesday, June 10, 2026. It is below its 12-month average by 3.11% (4.82%).
IQV Return on Assets (ROA) Chart
IQV Average Return on Assets (ROA) Chart
IQV Current vs Average Return on Assets (ROA) Chart
IQV Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
4.67%
RETURN ON ASSETS (ROA) AVG TTM
4.82%
RETURN ON ASSETS (ROA) AVG 3Y
4.76%
RETURN ON ASSETS (ROA) AVG 5Y
4.01%
RETURN ON ASSETS (ROA) AVG 10Y
3.84%
RETURN ON ASSETS (ROA) AVG 15Y
4.87%
RETURN ON ASSETS (ROA) AVG 20Y
4.87%
CURRENT VS TTM AVG
-3.11%
CURRENT VS 3Y AVG
-1.89%
CURRENT VS 5Y AVG
+16.31%
CURRENT VS 10Y AVG
+21.67%
CURRENT VS 15Y AVG
-4.08%
CURRENT VS 20Y AVG
-4.08%
IQV Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $30.60B | 4.67% | 4.82% | 4.76% | 4.01% |
| Medline Inc. (MDLN) | $30.90B | 2.47% | 3.17% | 1.75% | 1.75% |
| Centene Corporation (CNC) | $31.94B | -7.94% | -2.29% | 0.04% | 0.75% |
| DexCom, Inc. (DXCM) | $29.24B | 14.03% | 11.04% | 9.26% | 8.83% |
| Biogen Inc. (BIIB) | $29.00B | 4.65% | 5.11% | 6.74% | 8.29% |
| Zoetis Inc. (ZTS) | $34.20B | 17.44% | 17.37% | 16.33% | 15.33% |
| Veeva Systems Inc. (VEEV) | $26.73B | 10.31% | 9.93% | 9.72% | 10.43% |
| Agilent Technologies, Inc. (A) | $37.17B | 10.82% | 10.56% | 11.14% | 10.55% |
| Waters Corporation (WAT) | $23.83B | 1.83% | 13.34% | 15.53% | 17.15% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 23.85% | 25.02% | 24.63% | 23.85% |
Asset Efficiency
ROA
4.7%
ROE
22.3%
IQVIA Holdings Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for IQVIA Holdings Inc. (IQV)?
- The return on assets (ROA) for IQV stock is 4.67%.
- Is IQVIA Holdings Inc.'s return on assets (ROA) high or low?
- IQVIA Holdings Inc.'s return on assets (ROA) of 4.67% is 16% above its 5-year average of 4.01%, near the high end of its 5-year range (1.14%–5.10%).
- What is the TTM average return on assets (ROA) for IQVIA Holdings Inc. (IQV)?
- The TTM average return on assets (ROA) for IQV stock is 4.82%.
- What is the 3Y average return on assets (ROA) for IQVIA Holdings Inc. (IQV)?
- The 3Y average return on assets (ROA) for IQV stock is 4.76%.
- What is the 5Y average return on assets (ROA) for IQVIA Holdings Inc. (IQV)?
- The 5Y average return on assets (ROA) for IQV stock is 4.01%.
- What is the 10Y average return on assets (ROA) for IQVIA Holdings Inc. (IQV)?
- The 10Y average return on assets (ROA) for IQV stock is 3.84%.
- What is the 15Y average return on assets (ROA) for IQVIA Holdings Inc. (IQV)?
- The 15Y average return on assets (ROA) for IQV stock is 4.87%.
- What is the 20Y average return on assets (ROA) for IQVIA Holdings Inc. (IQV)?
- The 20Y average return on assets (ROA) for IQV stock is 4.87%.
IQVIA Holdings Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 4.54% |
| 2024-12-31 | 5.10% |
| 2023-12-31 | 5.09% |
| 2022-12-31 | 4.31% |
| 2021-12-31 | 3.91% |
| 2020-12-31 | 1.14% |
| 2019-12-31 | 0.82% |
| 2018-12-31 | 1.15% |
| 2017-12-31 | 5.76% |
| 2016-12-31 | 0.54% |
| 2015-12-31 | 9.86% |
| 2014-12-31 | 10.78% |
| 2013-12-31 | 7.39% |
| 2012-12-31 | 7.10% |
| 2011-12-31 | 10.41% |
| 2010-12-31 | 0.00% |
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib